In primary samples from AML patients, pyrvinium appeared more active in PTPN11 and KRAS than in NRAS mutants, while the opposite was seen for trametinib and interestingly, all but one sample were more sensitive to the combination of the two compounds compared to single-agents. This evidence concerns the gene KRAS and acute myeloid leukemia.